Pandemic Anti-Monopoly Act of 2020 This bill places a moratorium on certain mergers and acquisitions during the COVID-19 (i.e., coronavirus disease 2019) pandemic. Specifically, the bill prohibits certain transactions such as acquisitions (1) by firms with over $100 million in revenue; (2) by financial institutions or equity funds with over $100 million in capitalization; and (3) involving firms with exclusive patents pertaining to COVID-19 pandemic-related production, manufacturing, distribution, or infrastructure. However, a waiver may be granted if the participating firms demonstrate that the transaction will advance critical national security, economic, or public health interests during the emergency. Further, the bill establishes a legal presumption against a transaction that may pose a risk to the government's ability to respond to the national emergency declared due to COVID-19.
Administrative law and regulatory proceduresAdministrative remediesBanking and financial institutions regulationCardiovascular and respiratory healthCivil actions and liabilityCompetition and antitrustCorporate finance and managementDrug safety, medical device, and laboratory regulationEmergency medical services and trauma careFederal Trade Commission (FTC)Financial services and investmentsHealth technology, devices, suppliesInfectious and parasitic diseasesIntellectual propertyManufacturingProduct development and innovationPublic contracts and procurementResearch and developmentStrategic materials and reserves
Pandemic Anti-Monopoly Act of 2020
USA116th CongressHR-6989| House
| Updated: 5/22/2020
Pandemic Anti-Monopoly Act of 2020 This bill places a moratorium on certain mergers and acquisitions during the COVID-19 (i.e., coronavirus disease 2019) pandemic. Specifically, the bill prohibits certain transactions such as acquisitions (1) by firms with over $100 million in revenue; (2) by financial institutions or equity funds with over $100 million in capitalization; and (3) involving firms with exclusive patents pertaining to COVID-19 pandemic-related production, manufacturing, distribution, or infrastructure. However, a waiver may be granted if the participating firms demonstrate that the transaction will advance critical national security, economic, or public health interests during the emergency. Further, the bill establishes a legal presumption against a transaction that may pose a risk to the government's ability to respond to the national emergency declared due to COVID-19.
Administrative law and regulatory proceduresAdministrative remediesBanking and financial institutions regulationCardiovascular and respiratory healthCivil actions and liabilityCompetition and antitrustCorporate finance and managementDrug safety, medical device, and laboratory regulationEmergency medical services and trauma careFederal Trade Commission (FTC)Financial services and investmentsHealth technology, devices, suppliesInfectious and parasitic diseasesIntellectual propertyManufacturingProduct development and innovationPublic contracts and procurementResearch and developmentStrategic materials and reserves